Backed by part­ners at Pfiz­er, eF­FEC­TOR brings its VC to­tal to $150M as PhII can­cer tri­al looms

With a big as­sist from its Big Phar­ma col­lab­o­ra­tor Pfiz­er, San Diego-based eF­FEC­TOR Ther­a­peu­tics has now added a $38.5 mil­lion round to pay for a Phase II pro­gram to test the com­bi­na­tion of its oral im­muno-ther­a­py drug with avelum­ab (Baven­cio) — Pfiz­er and Mer­ck KGaA’s PD-L1 check­point in­hibitor.

The round com­pletes a se­ries of moves by eF­FEC­TOR, which has moved from pre­clin­i­cal tests to check on the po­ten­tial of a com­bo to ear­ly-stage monother­a­py work to test the drug in a small group of can­cer pa­tients. Pfiz­er had agreed to share the costs of the com­ing Phase II tri­als with eF­FEC­TOR, and Pfiz­er Ven­ture In­vest­ments took the lead on the new round, which brings its to­tal raised to $150 mil­lion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN